A detailed history of Parallel Advisors, LLC transactions in E Ffector Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 67,738 shares of EFTR stock, worth $3,386. This represents 0.03% of its overall portfolio holdings.

Number of Shares
67,738
Previous 1,693,559 96.0%
Holding current value
$3,386
Previous $795,000 22.52%
% of portfolio
0.03%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$0.42 - $16.95 $682,844 - $27.6 Million
-1,625,821 Reduced 96.0%
67,738 $974,000
Q1 2023

May 20, 2024

BUY
$0.35 - $0.67 $569,037 - $1.09 Million
1,625,821 Added 2400.16%
1,693,559 $592,000
Q2 2022

Aug 01, 2022

BUY
$1.3 - $3.84 $1.32 Million - $3.9 Million
1,016,107 Added 149.99%
1,693,559 $2.41 Million
Q1 2022

Apr 28, 2022

BUY
$3.85 - $8.2 $2.61 Million - $5.56 Million
677,452 New
677,452 $2.74 Million

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Market Cap $2.07M
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.